In an experiment evaluating the first topical gene treatment ever, youngsters with a rare blistering skin illness showed remarkable improvements. Long-open wounds were shown to totally heal after application of the gene therapy gel. An uncommon skin condition called dystrophic epidermolysis bullosa (DEB) causes the skin to blister continuously and frequently leaves open lesions that are not able to heal. The disorder is brought on by a mutation in the COL7A1 gene, which prevents the production of a crucial collagen protein. The new treatment is a gel that is intended to directly deliver functional copies of the COL7A1 gene to damaged tissue. Theoretically, this ought to stimulate the formation of vital collagen proteins required for skin healing. Despite its inability to multiply or spread to other parts of the body, a modified herpes virus used to deliver functional genes is able to evade the body's immune systems. Unfortunately, because the gel's effects are temporary, several patients have experienced the reappearance of some of their wounds in the months following the trial's conclusion. The researchers state that this is to be anticipated, but given that there were no side effects observed after administering the gel repeatedly, it is likely that continued treatments could be helpful for a considerable amount of time.